(Q46193261)

English

Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19091199

Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19091199

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

author name string

Angel Rodríguez

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19091199

Jesús Reviriego

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19091199

Pepa Polavieja

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19091199

Jordi Mesa

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19091199

language of work or name

0 references

publication date

1 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19091199

Medicina clínica

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19091199

131

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19091199

19

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19091199

721-730

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19091199

Diabetes trends in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Emerging epidemic of type 2 diabetes in youth

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Epidemiology of diabetes and its non-coronary complications

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Evolution of prevalence of type 2 diabetes in adult Spanish population

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Direct health care costs of diabetic patients in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Management of type 2 diabetic patients in primary care in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

PREVENCAT study: control of cardiovascular risk in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Type 2 diabetes: principles of pathogenesis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Comparison of methods to identify individuals at increased risk of coronary disease from the general population.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Variability in the presence of the metabolic syndrome in Type 2 diabetic patients attending a diabetes clinic. Influences of age and gender

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2808%2975486-1

7 January 2021

Identifiers

10.1016/S0025-7753(08)75486-1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19091199

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19091199

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46193261&oldid=2099064934"